Perspective Therapeutics (NYSEAMERICAN:CATX) Insider Markus Puhlmann Purchases 35,000 Shares of Company Stock

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) insider Markus Puhlmann bought 35,000 shares of the stock in a transaction dated Thursday, November 12th. The shares were acquired at an average cost of $0.84 per share, for a total transaction of $29,400.00. Following the completion of the acquisition, the insider directly owned 178,542 shares of the company’s stock, valued at approximately $149,975.28. This trade represents a 24.38% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Markus Puhlmann also recently made the following trade(s):

• On Wednesday, November 11th, Markus Puhlmann purchased 6,000 shares of Perspective Therapeutics stock. The stock was acquired at an average price of $0.83 per share, with a total value of $4,980.00.

Perspective Therapeutics Stock Up 12.0%

NYSEAMERICAN:CATX traded up $0.10 during trading hours on Friday, reaching $0.94. 3,183,208 shares of the company were exchanged, compared to its average volume of 4,328,272. The business has a 50 day moving average of $2.11 and a 200 day moving average of $3.44. Perspective Therapeutics, Inc. has a 1-year low of $0.78 and a 1-year high of $6.16. The company has a current ratio of 5.18, a quick ratio of 6.61 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. On average, equities research analysts anticipate that Perspective Therapeutics, Inc. will post -1.01 EPS for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Provenance Wealth Advisors LLC bought a new position in Perspective Therapeutics in the 3rd quarter valued at approximately $44,000. Auctus Advisors LLC grew its stake in shares of Perspective Therapeutics by 83.6% during the third quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock worth $103,000 after buying an additional 17,015 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Perspective Therapeutics by 53.1% during the third quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock worth $168,000 after buying an additional 21,150 shares in the last quarter. Quantinno Capital Management LP acquired a new position in shares of Perspective Therapeutics during the first quarter worth $273,000. Finally, Taylor & Morgan Wealth Management LLC increased its holdings in shares of Perspective Therapeutics by 127.6% during the second quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock worth $225,000 after buying an additional 37,000 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Piper Sandler reduced their price objective on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Wedbush restated an “outperform” rating and issued a $7.00 target price (down from $9.00) on shares of Perspective Therapeutics in a research report on Tuesday, November 10th. William Blair assumed coverage on shares of Perspective Therapeutics in a report on Friday, September 18th. They set an “outperform” rating for the company. Bank of America reduced their price target on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. Finally, Royal Bank Of Canada cut shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $14.00 to $4.00 in a research note on Monday, October 26th. Nine analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.10.

More Perspective Therapeutics News

These are some of the CATX news items that stood out recently:

• Positive Sentiment: CEO Johan Spoor bought 47,000 shares at an average price of $0.81, increasing his holdings by 79%. Insider Markus Puhlmann also bought 41,000 shares across two transactions at average prices of $0.83 and $0.84. These open-market purchases may signal insiders’ confidence in the company. Insider purchase report
• Positive Sentiment: BMO Capital gave CATX a Buy rating, adding a bullish analyst view. BMO Capital rating
• Neutral Sentiment: Brookline Capital Markets made slightly different revisions to its earnings forecasts: it raised its Q4 2026 estimate to a loss of $0.25 per share from $0.26, but lowered its full-year estimate to a loss of $1.00 from $0.99. Perspective Therapeutics analyst estimates

Perspective Therapeutics Company Profile

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.